Cargando…

The Sensitivity of Diffuse Large B-Cell Lymphoma Cell Lines to Histone Deacetylase Inhibitor-Induced Apoptosis Is Modulated by BCL-2 Family Protein Activity

BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is a genetically heterogeneous disease and this variation can often be used to explain the response of individual patients to chemotherapy. One cancer therapeutic approach currently in clinical trials uses histone deacetylase inhibitors (HDACi’s) as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thompson, Ryan C., Vardinogiannis, Iosif, Gilmore, Thomas D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647059/ https://www.ncbi.nlm.nih.gov/pubmed/23667527 http://dx.doi.org/10.1371/journal.pone.0062822

Ejemplares similares

Expression of Histone Deacetylases in Diffuse Large B-cell Lymphoma and Its Clinical Significance
por: Lee, Sung Hak, et al.
Publicado: (2014)

Glioma Stem Cells Are Sensitized to BCL-2 Family Inhibition by Compromising Histone Deacetylases
por: Merati, Aran, et al.
Publicado: (2023)

Identification of an NF-κB p50/p65-responsive site in the human MIR155HG promoter
por: Thompson, Ryan C, et al.
Publicado: (2013)

Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy
por: Haery, Leila, et al.
Publicado: (2015)

The effects of a histone deacetylase inhibitor on biological behavior of diffuse large B-cell lymphoma cell lines and insights into the underlying mechanisms
por: Cai, Ying, et al.
Publicado: (2013)

A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors
por: Tula-Sanchez, Ana A, et al.
Publicado: (2013)

The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma
por: Dias, Joana N.R., et al.
Publicado: (2018)

Single‐cell profiling‐guided combination therapy of c‐Fos and histone deacetylase inhibitors in diffuse large B‐cell lymphoma
por: Wang, Luqiao, et al.
Publicado: (2022)

Single‐cell profiling guided combination therapy of c‐Fos and histone deacetylase inhibitors in diffuse large B‐cell lymphoma
por: Krämer, Oliver H., et al.
Publicado: (2022)

Increased histone deacetylase 6 expression serves as a favorable prognostic factor for diffuse large B-cell lymphoma
por: Lin, Xiao-Ji, et al.
Publicado: (2017)

Histone Deacetylase Inhibitors Sensitize TRAIL-Induced Apoptosis in Colon Cancer Cells
por: Zhang, Baojie, et al.
Publicado: (2019)

Anti-Cancer Effects of CKD-581, a Potent Histone Deacetylase Inhibitor against Diffuse Large B-Cell Lymphoma
por: Kim, Soo Jin, et al.
Publicado: (2020)

Histone deacetylase inhibitors in Hodgkin lymphoma
por: Buglio, Daniela, et al.
Publicado: (2010)

The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines
por: Cosenza, Maria, et al.
Publicado: (2016)

Reciprocal sensitivity of diffuse large B-cell lymphoma cells to Bcl-2 inhibitors BIRD-2 versus venetoclax
por: Vervloessem, Tamara, et al.
Publicado: (2017)

Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas
por: Zhang, Qing, et al.
Publicado: (2019)

Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL)
por: Lu, Guang, et al.
Publicado: (2023)

Endogenous Neurotrophins and Trk Signaling in Diffuse Large B Cell Lymphoma Cell Lines Are Involved in Sensitivity to Rituximab-Induced Apoptosis
por: Bellanger, Cynthia, et al.
Publicado: (2011)

Diffuse Large B-Cell Lymphoma in Kenya: MYC, BCL2, and the Cell of Origin
por: Wawire, Jonathan, et al.
Publicado: (2019)

The Histone Deacetylase Inhibitor LBH589 (Panobinostat) Modulates the Crosstalk of Lymphocytes with Hodgkin Lymphoma Cell Lines
por: Klein, Jan M., et al.
Publicado: (2013)

Paradoxical Regulation of Hypoxia Inducible Factor-1α (HIF-1α) by Histone Deacetylase Inhibitor in Diffuse Large B-Cell Lymphoma
por: Bhalla, Savita, et al.
Publicado: (2013)

Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition
por: Flatmark, Kjersti, et al.
Publicado: (2006)

Effects of histone deacetylase inhibitor trichostatin A combined with cisplatin on apoptosis of A549 cell line
por: Zhang, Xuan, et al.
Publicado: (2015)

Histone deacetylase 6 activity is critical for the metastasis of Burkitt’s lymphoma cells
por: Ding, Ning, et al.
Publicado: (2014)

miR-10a inhibits cell proliferation and promotes cell apoptosis by targeting BCL6 in diffuse large B-cell lymphoma
por: Fan, Qian, et al.
Publicado: (2016)

Establishment and characterization of a novel MYC/BCL2 “double-hit” diffuse large B cell lymphoma cell line, RC
por: Pham, Lan V., et al.
Publicado: (2015)

Primary cutaneous diffuse large B‐cell lymphoma, leg type with MYC/BCL2/BCL6 overexpression
por: Okada, Yosuke, et al.
Publicado: (2021)

Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma
por: Ramakrishnan, Vijay G., et al.
Publicado: (2019)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Dual Inhibition of Histone Deacetylases and the Mechanistic Target of Rapamycin Promotes Apoptosis in Cell Line Models of Uveal Melanoma
por: Patel, Ruchi P., et al.
Publicado: (2021)

Specific interactions of BCL-2 family proteins mediate sensitivity to BH3-mimetics in diffuse large B-cell lymphoma
por: Smith, Victoria M., et al.
Publicado: (2020)

Copy Number Alteration and Mutational Profile of High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements, Diffuse Large B-Cell Lymphoma with MYC-Rearrangement, and Diffuse Large B-Cell Lymphoma with MYC-Cluster Amplification
por: Miyaoka, Masashi, et al.
Publicado: (2022)

Histone acetyltransferase-deficient p300 mutants in diffuse large B cell lymphoma have altered transcriptional regulatory activities and are required for optimal cell growth
por: Haery, Leila, et al.
Publicado: (2014)

Histone Deacetylase Inhibition: An Important Mechanism in the Treatment of Lymphoma
por: Guo, Shan-qi, et al.
Publicado: (2012)

AID assists DNMT1 to attenuate BCL6 expression through DNA methylation in diffuse large B-cell lymphoma cell lines
por: Jiao, Junna, et al.
Publicado: (2020)

Inhibition of Histone Deacetylase 3 Causes Replication Stress in Cutaneous T Cell Lymphoma
por: Wells, Christina E., et al.
Publicado: (2013)

Recalcitrant Subcutaneous Panniculitis-Like T-Cell Lymphoma Responsive to Histone Deacetylase Inhibitor
por: Gleason, Laura, et al.
Publicado: (2022)

Primary breast diffuse large B cell lymphoma
por: Guo, Mengni, et al.
Publicado: (2022)

Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression
por: Raha, Paromita, et al.
Publicado: (2015)

Quantitative Acetylomics Uncover Acetylation-Mediated Pathway Changes Following Histone Deacetylase Inhibition in Anaplastic Large Cell Lymphoma
por: Zrimšek, Maša, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cvru8d0qtr93h4g62ruai4r16a